<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>STAR</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">STAR</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="strides-pharma-science-limited" class="section level1">
<h1>Strides Pharma Science Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.STAR.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.STAR.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.STAR.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.STAR.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.STAR.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.STAR.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.STAR.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.STAR.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.STAR.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-10 </em></p>
<div id="analysis-of-star-strides-pharma-science-limited" class="section level9">
<p class="heading"><strong>Analysis of STAR (Strides Pharma Science Limited)</strong></p>
<p><strong>Stock Codes:</strong> BSE: 532531 | NSE: STAR<br />
<strong>Report Date:</strong> November 17, 2025</p>
<hr />
</div>
<div id="executive-summary" class="section level6">
<h6><strong>Executive Summary</strong></h6>
<p>Strides Pharma Science Limited (STAR) delivered a <strong>robust performance in Q2FY26</strong>, marked by strong year-on-year (YoY) growth across key profitability metrics, including a <strong>record quarterly EPS of ₹15.2</strong> and an <strong>84.3% YoY growth in operational PAT</strong>. This performance underscores its improving operating discipline, margin expansion, and strategic focus on profitable markets.</p>
<p>However, growth is uneven across segments, and <strong>external headwinds—particularly in currency, donor funding, and intense generic market competition—pose near-term challenges</strong>. The company’s long-term prospects hinge on its <strong>“Beyond Generics” pipeline</strong>, <strong>pan-European B2B partnerships</strong>, and <strong>expansion into emerging geographies</strong>.</p>
<p>This analysis details the <strong>tailwinds, headwinds, growth drivers, and risks</strong> in the context of STAR’s financial performance, strategic direction, and macro-industry environment.</p>
<hr />
</div>
<div id="tailwinds-key-growth-drivers-strengths" class="section level6">
<h6><strong>1. Tailwinds: Key Growth Drivers &amp; Strengths</strong></h6>
<div id="strong-profitability-momentum" class="section level9">
<p class="heading"><strong>1.1 Strong Profitability Momentum</strong></p>
<ul>
<li><strong>Operational PAT: ₹1,403m (Q2FY26)</strong> → up <strong>84.3% YoY</strong>, outpacing revenue growth.</li>
<li><strong>Gross margin expansion</strong>: Margin improved to <strong>57.8%</strong> (+500 bps YoY), driven by cost optimization, product mix, and operational efficiency.</li>
<li><strong>EBITDA growth</strong>: Up <strong>25.4% YoY</strong> to ₹2,316m with margin at <strong>19.0%</strong> (up 320 bps YoY).</li>
<li><strong>Record EPS</strong>: ₹15.2 (vs. ₹8.3 in Q2FY25), highest ever quarterly EPS, showing strong capital efficiency.</li>
</ul>
<blockquote>
<p><strong>Indicator</strong>: Focus on profitability over volume is yielding results and improving return metrics.</p>
</blockquote>
</div>
<div id="growth-in-other-regulated-markets-orm-key-engine-of-growth" class="section level9">
<p class="heading"><strong>1.2 Growth in Other Regulated Markets (ORM) – Key Engine of Growth</strong></p>
<ul>
<li><strong>ORM revenue: $44m (₹3.842B)</strong> → <strong>+16% YoY</strong>.</li>
<li>Growth driven by <strong>B2B partnerships in Europe</strong>, especially with large pan-EU partners.</li>
<li><strong>Strong customer advocacy and dependable supply</strong> enabling <strong>new customer acquisition and portfolio expansion</strong>.</li>
<li><strong>Robust regulatory filing pipeline</strong> supports medium-term growth.</li>
</ul>
<blockquote>
<p><strong>Strategy</strong>: ORM is positioned as a strategic growth pillar, leveraging reliable supply chains and strategic alliances.</p>
</blockquote>
</div>
<div id="financial-discipline-and-balance-sheet-strengthening" class="section level9">
<p class="heading"><strong>1.3 Financial Discipline and Balance Sheet Strengthening</strong></p>
<ul>
<li><strong>Net debt reduced by ₹733m in H1FY26</strong> despite:
<ul>
<li>₹1,492m capex (including intangibles),</li>
<li>₹710m adverse currency impact.</li>
</ul></li>
<li><strong>Net debt down ₹469m in Q2 alone.</strong></li>
<li><strong>Operating cash flow: ₹3,915m in H1FY26</strong> → strong internal accrual generation.</li>
<li><strong>Net debt to EBITDA (TTM)</strong>: 1.7x (down from 3.5x in FY24).</li>
<li><strong>RoCE (TTM)</strong>: Improved to <strong>16.0%</strong> (from 9.7% in FY24).</li>
</ul>
<blockquote>
<p><strong>Governance win</strong>: Balance sheet reset post-demerger is bearing fruit, with improved leverage, cash flow, and investor confidence.</p>
</blockquote>
</div>
<div id="strategic-push-beyond-generics" class="section level9">
<p class="heading"><strong>1.4 Strategic Push Beyond Generics</strong></p>
<ul>
<li><strong>First “Beyond Generics” product (Nasal Spray) filed with USFDA</strong>.</li>
<li>Entry into <strong>Controlled Substances and 505(b)(2)</strong> pathways:
<ul>
<li>Higher margins and lower competition.</li>
<li>Long-term differentiation from commoditized generics space.</li>
</ul></li>
<li>Platform expansion into <strong>higher-value therapeutic niches</strong>.</li>
</ul>
<blockquote>
<p><strong>Long-term story</strong>: Moves to reduce dependency on traditional generics and build sustainable IP-adjacent revenue.</p>
</blockquote>
</div>
<div id="us-generics-business-stability-and-revival-plan" class="section level9">
<p class="heading"><strong>1.5 US Generics Business Stability and Revival Plan</strong></p>
<ul>
<li><strong>Q2FY26 US revenue: $73m</strong> → <strong>+2% YoY</strong>, despite intense competition in recent launches.</li>
<li><strong>70 commercialized products</strong>, with <strong>37 in top 3 market share (75% of US revenue)</strong>.</li>
<li>Strategy to relaunch <strong>60 dormant ANDAs</strong> over next 3 years to target <strong>$400m generics revenue by FY27–28</strong>.</li>
<li><strong>230+ ANDAs filed, 215+ approved</strong> as of July 2025.</li>
</ul>
<blockquote>
<p><strong>Resilience</strong>: Core US business is stable and rebuilding momentum despite challenges.</p>
</blockquote>
</div>
<div id="expanding-footprint-in-growth-markets-africa-latam-mena-apac" class="section level9">
<p class="heading"><strong>1.6 Expanding Footprint in Growth Markets (Africa, LATAM, MENA, APAC)</strong></p>
<ul>
<li><strong>Growth Markets revenue: $17m (₹1,468m) in Q2FY26</strong>, up <strong>7% YoY</strong>.</li>
<li>Growth driven by <strong>Africa operations and new product launches</strong>.</li>
<li>“<strong>In Africa for Africa</strong>” strategy enhancing localization and market penetration.</li>
<li>Pipeline of <strong>regulatory filings in new geographies</strong>, though timelines are long.</li>
</ul>
<blockquote>
<p><strong>Sustainable tailwind</strong>: Addressing underserved markets with customized product portfolios.</p>
</blockquote>
<hr />
</div>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>2. Headwinds &amp; Challenges</strong></h6>
<div id="subdued-access-markets-due-to-donor-funding-challenges" class="section level9">
<p class="heading"><strong>2.1 Subdued Access Markets Due to Donor Funding Challenges</strong></p>
<ul>
<li><strong>Access Markets revenue: $7m (₹609m)</strong> → <strong>-25% YoY</strong>.</li>
<li>Driven by <strong>tightening donor funding (e.g., Global Fund, PEPFAR)</strong>.</li>
<li>Historically significant for institutional supply, especially in public health programs.</li>
<li>Company acknowledges <strong>“challenging donor funding environment”</strong>.</li>
</ul>
<blockquote>
<p><strong>Risk</strong>: Donor dependency makes this segment vulnerable to geopolitical and budgetary shifts.</p>
</blockquote>
</div>
<div id="intense-competition-in-us-generics" class="section level9">
<p class="heading"><strong>2.2 Intense Competition in US Generics</strong></p>
<ul>
<li><strong>US market flat (+2% YoY)</strong> despite new launches due to <strong>rapid entry of new competitors</strong>.</li>
<li>Pricing pressure persists in highly competitive generics space.</li>
<li>Revival of <strong>dormant ANDAs</strong> required to achieve $400m target but execution risk remains.</li>
</ul>
<blockquote>
<p><strong>Threat</strong>: Without differentiation (via 505(b)(2) or new formulations), revenue growth may stall.</p>
</blockquote>
</div>
<div id="currency-volatility" class="section level9">
<p class="heading"><strong>2.3 Currency Volatility</strong></p>
<ul>
<li><strong>Adverse forex impact of ₹710m in H1FY26</strong>.</li>
<li>Company earning in USD/EUR but costs in INR → FX volatility erodes margins.</li>
<li>Net debt reduction <strong>achieved despite headwinds</strong>, but risk persists.</li>
</ul>
<blockquote>
<p><strong>Macroeconomic risk</strong>: INR appreciation or dollar volatility can pressure margins and cash flows.</p>
</blockquote>
</div>
<div id="lumpy-growth-in-emerging-markets" class="section level9">
<p class="heading"><strong>2.4 Lumpy Growth in Emerging Markets</strong></p>
<ul>
<li><strong>Growth Markets to have “lumpy quarters”</strong> for next 2 years due to:
<ul>
<li>Long regulatory timelines.</li>
<li>Gradual market stabilization.</li>
</ul></li>
<li>Unpredictable revenue patterns may affect investor sentiment.</li>
</ul>
<blockquote>
<p><strong>Volatility</strong>: Early-stage expansion introduces uncertainty in quarterly performance.</p>
</blockquote>
</div>
<div id="high-leverage-of-exceptional-items-in-prior-periods" class="section level9">
<p class="heading"><strong>2.5 High Leverage of Exceptional Items in Prior Periods</strong></p>
<ul>
<li><strong>H1FY25 reported PAT was ₹34.2B</strong>, primarily due to <strong>₹31.9B profit from discontinued operations</strong> (demerger of Softgel business to OneSource).</li>
<li>Future comparability distorted by base effects.</li>
<li>Current “operational PAT” strips this out for clarity, but investors must remain cautious.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects-strategic-outlook" class="section level6">
<h6><strong>3. Growth Prospects &amp; Strategic Outlook</strong></h6>
<table>
<colgroup>
<col width="42%" />
<col width="36%" />
<col width="21%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Market Segment</strong></th>
<th><strong>Growth Strategy</strong></th>
<th><strong>Potential</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>US Generics</strong></td>
<td>Relaunch 60 dormant ANDAs targeting cost leadership; sustained top 3 rankings</td>
<td>Target: <strong>$400m revenue by FY27–28</strong></td>
</tr>
<tr class="even">
<td><strong>Beyond Generics</strong></td>
<td>Invest in <strong>505(b)(2), nasal sprays, controlled substances</strong>; first product filed with USFDA</td>
<td>High-margin diversification; potential valuation rerating</td>
</tr>
<tr class="odd">
<td><strong>Other Regulated Markets (Europe, etc.)</strong></td>
<td>Expand <strong>pan-EU B2B partnerships</strong>, regulatory filings, new customers</td>
<td><strong>Sustainable double-digit growth</strong> path</td>
</tr>
<tr class="even">
<td><strong>Growth Markets (Africa, LATAM, MENA, APAC)</strong></td>
<td>“In Africa for Africa”; new product launches, channel partner expansion</td>
<td>Long-term structural growth; lumpy in near term</td>
</tr>
<tr class="odd">
<td><strong>Access Markets</strong></td>
<td>Stabilize operations amid donor environment challenges</td>
<td>Recovery dependent on funding restoration</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Overall Outlook</strong>: Management reaffirms long-term vision of <strong>sustainable, profitable growth</strong>—not just scale.</p>
</blockquote>
<hr />
</div>
<div id="key-risks" class="section level6">
<h6><strong>4. Key Risks</strong></h6>
<table>
<colgroup>
<col width="45%" />
<col width="22%" />
<col width="32%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk</strong></th>
<th><strong>Description</strong></th>
<th><strong>Mitigation/Exposure</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Donor Funding Volatility</strong></td>
<td>Access markets rely on donor budgets (e.g., HIV/AIDS, malaria therapies).</td>
<td>Limited control; diversification into commercial markets ongoing.</td>
</tr>
<tr class="even">
<td><strong>Intense Generics Competition</strong></td>
<td>US market saturated; new entrants erode pricing and market share.</td>
<td>Focus on <strong>differentiated, niche products</strong> via 505(b)(2); operational efficiency.</td>
</tr>
<tr class="odd">
<td><strong>Regulatory Delays</strong></td>
<td>Global approvals (especially EU, US, Africa) face delays; impacts revenue timing.</td>
<td>Regulatory filings ongoing; experienced team, but timelines uncertain.</td>
</tr>
<tr class="even">
<td><strong>Currency Risk</strong></td>
<td>Revenue in USD/EUR; costs in INR → FX impact on margins and debt.</td>
<td>Natural hedging via overseas ops; some exposure unavoidable.</td>
</tr>
<tr class="odd">
<td><strong>Execution Risk in “Beyond Generics”</strong></td>
<td>New pathways (505(b)(2)) require higher R&amp;D, regulatory agility, and capital.</td>
<td>Early-stage filings show commitment; track delivery over next 18–24 months.</td>
</tr>
<tr class="even">
<td><strong>Capex Funding Constraints</strong></td>
<td>Capex of ₹1.5B in H1 funded internally, but scaling may require external support.</td>
<td>Strong cash flows help, but aggressive expansion could pressure balance sheet.</td>
</tr>
<tr class="odd">
<td><strong>Geopolitical Risk (Africa, LATAM)</strong></td>
<td>Operations in politically unstable regions.</td>
<td>Localized operations mitigate some risk; but supply chain exposure exists.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="financial-snapshot-q2fy26" class="section level6">
<h6><strong>5. Financial Snapshot (Q2FY26)</strong></h6>
<table>
<thead>
<tr class="header">
<th><strong>Metric</strong></th>
<th><strong>Q2 FY26</strong></th>
<th><strong>YoY Change</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Revenue</td>
<td>₹12,208m</td>
<td>+4.6%</td>
</tr>
<tr class="even">
<td>Gross Margin</td>
<td>₹7,056m</td>
<td>+14.6%</td>
</tr>
<tr class="odd">
<td>Gross Margin %</td>
<td>57.8%</td>
<td>+500 bps</td>
</tr>
<tr class="even">
<td>EBITDA</td>
<td>₹2,316m</td>
<td>+25.4%</td>
</tr>
<tr class="odd">
<td>EBITDA Margin</td>
<td>19.0%</td>
<td>+320 bps</td>
</tr>
<tr class="even">
<td>Operational PAT</td>
<td>₹1,403m</td>
<td>+84.3%</td>
</tr>
<tr class="odd">
<td>Reported PAT</td>
<td>₹1,315m</td>
<td>+81.9% (vs ₹723m)</td>
</tr>
<tr class="even">
<td>Operational EPS</td>
<td>₹15.2</td>
<td>+83.8%</td>
</tr>
<tr class="odd">
<td>Net Debt</td>
<td>₹14,489m</td>
<td>-₹469m (vs Q1)</td>
</tr>
<tr class="even">
<td>Cash Flow from Operations</td>
<td>₹3,915m (H1)</td>
<td>Strong accruals</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="valuation-implications" class="section level6">
<h6><strong>6. Valuation Implications</strong></h6>
<ul>
<li><strong>Strong earnings momentum</strong> and improving RoCE suggest <strong>potential re-rating catalyst</strong>.</li>
<li><strong>Operational de-risking</strong> post-demerger and debt reduction make STAR more attractive.</li>
<li><strong>Shift from generics to 505(b)(2)/niches</strong> could improve valuation multiples over time.</li>
<li><strong>Near-term P/E looks reasonable</strong> given profitability surge, but dependent on sustaining growth.</li>
</ul>
<hr />
</div>
<div id="conclusion-buy-case-vs.-caution" class="section level6">
<h6><strong>7. Conclusion: Buy Case vs. Caution</strong></h6>
<div id="bull-case-buyhold" class="section level9">
<p class="heading">✅ <strong>Bull Case (Buy/Hold)</strong></p>
<ul>
<li>Profitability is accelerating with <strong>best-ever EPS</strong>.</li>
<li>Balance sheet has significantly improved with <strong>debt reduction and strong cash flow</strong>.</li>
<li>Strategic pivot into <strong>higher-margin, less competitive “Beyond Generics”</strong> adds long-term optionality.</li>
<li>ORM and Growth Markets provide <strong>diversified revenue base</strong>.</li>
<li>Management demonstrates <strong>strong execution and capital discipline</strong>.</li>
</ul>
</div>
<div id="bear-case-caution" class="section level9">
<p class="heading">⚠️ <strong>Bear Case (Caution)</strong></p>
<ul>
<li><strong>Growth lags profitability</strong>: Revenue up only <strong>4.6% YoY</strong>.</li>
<li><strong>Access Markets in decline</strong> due to donor dependency.</li>
<li><strong>ORM and new geographies</strong> face lumpy performance.</li>
<li><strong>US generics growth is muted</strong> and faces stiff competition.</li>
<li>Success depends on <strong>execution of long-term strategies (ANDA relaunch, 505(b)(2))</strong>, which carry risk.</li>
</ul>
<hr />
</div>
</div>
<div id="final-assessment" class="section level6">
<h6><strong>Final Assessment</strong></h6>
<table>
<thead>
<tr class="header">
<th><strong>Category</strong></th>
<th><strong>Assessment</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Financial Health</strong></td>
<td>✅ Strong &amp; Improving</td>
</tr>
<tr class="even">
<td><strong>Earnings Growth</strong></td>
<td>✅ Accelerating (PAT +84% YoY)</td>
</tr>
<tr class="odd">
<td><strong>Balance Sheet</strong></td>
<td>✅ De-risking (Net debt down ₹733m H1)</td>
</tr>
<tr class="even">
<td><strong>Revenue Quality</strong></td>
<td>⚠️ Mixed (ORM &amp; US stable, Access weak)</td>
</tr>
<tr class="odd">
<td><strong>Growth Prospects</strong></td>
<td>✅ Moderate to High (long-term)</td>
</tr>
<tr class="even">
<td><strong>Execution Risk</strong></td>
<td>⚠️ Moderate</td>
</tr>
<tr class="odd">
<td><strong>Valuation Potential</strong></td>
<td>✅ Upside if execution continues</td>
</tr>
</tbody>
</table>
<hr />
<div id="recommendation-accumulate-for-long-term-investors" class="section level9">
<p class="heading">✅ <strong>Recommendation: Accumulate for Long-Term Investors</strong></p>
<p>STRIDES (STAR) is transitioning from a <strong>transactional generics company</strong> to a <strong>profitable, diversified global pharma player</strong>. While revenue growth is modest, <strong>profitability, cash flow, and strategic diversification are strengthening</strong>.</p>
<p><strong>Ideal for:</strong><br />
- Investors seeking <strong>improving balance sheets</strong> and <strong>rising returns</strong>. - Those willing to <strong>wait 2–3 years</strong> for “Beyond Generics” and pan-EU/pan-Africa strategies to mature.</p>
<p><strong>Monitor:</strong><br />
- Progress on ANDA relaunches in US. - Commercialization of 505(b)(2)/nasal spray. - Donor funding stability. - Quarterly trends in Growth/Access Markets.</p>
<hr />
<p><strong>Final Note:</strong><br />
With <strong>strong governance, clear strategy, and execution on track</strong>, Strides is on a credible path to <strong>sustainable value creation</strong>. Risk-tolerant investors may find it an attractive turnaround story with above-average return potential.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
